Abstract: A method for producing liposomes entrapping Cyclosporine A (CsA). The method comprising preparing a suspension of CsA-free liposomes with a pH level of 7, preparing a mixture with a pH level of 7 by adding the suspension of CsA-free liposomes in the sucrose phosphate buffer to an ethanolic solution of CsA, and forming the liposomes entrapping CsA by incubating the mixture at a temperature level between 42° C. and 48° C. for a time duration between 55 and 65 minutes.

Abstract: A molecule comprising a lipid, a peptide and a linker to bind the lipid to the peptide which have specific amino acid sequence to bind to Epidermal Growth Factor Receptor (EGFR) of tumor cells, and a liposomal composition which is targeted by the molecule, and method for preparing thereof is disclosed.

Abstract: Disclosed is a liposomal composition for treatment of cancer, which includes at least one PEG-Phospholipid conjugated molecule, cholesterol, and at least one phospholipid.

Abstract: Anionic liposomes and apolipoprotein B-100 targeted immunoliposomes as therapeutic agents for dyslipidemia and related diseases, and compositions and methods for preparing same.

Abstract: A molecule comprising a lipid, a peptide and a linker to bind the lipid to the peptide which have specific amino acid sequence to bind to Epidermal Growth Factor Receptor (EGFR) of tumor cells, and a liposomal composition which is targeted by the molecule, and method for preparing thereof is disclosed.

Abstract: A method for preparing a liposome composition for delivering polyphenolic compounds to the target organs may include preparing a complex that contains at least one polyphenolic compound. Then, encapsulating the polyphenolic compound into a liposome composition by admixing the prepared complex with the liposome ingredients.

Abstract: Disclosed herein is a liposomal composition for treatment of cancer including PEGylated liposomes loaded by an anticancer drug, where the PEGylated liposome is further targeted by an effective number of P15 peptides.

Abstract: Disclosed is a liposomal composition for treatment of cancer, which includes at least one PEG-Phospholipid conjugated molecule, cholesterol, and at least one phospholipid.

Abstract: A liposomal composition for treatment of cancer including a PEGylated liposome loaded by an anthracycline chemotherapeutic agent, wherein the PEGylated liposome is further targeted by an effective number of affibody molecules.

Abstract: Anionic liposomes and apolipoprotein B-100 targeted immunoliposomes as therapeutic agents for dyslipidemia and related diseases, and compositions and methods for preparing same.

Abstract: A topical liposomal composition of Amphotricin B (AmB) and method for preparing same, which can be used as a composition and method for preparing topical liposomal compositions of other hydrophobic drugs. The formulation using AmphotricinB can be used for treating fungal or protozoan infections. The composition is stable with no significant changes in the sizes and AmB content of liposomes after storing at 4° C. and room temperature (22° C.) for more than 20 months. In in vivo and in vitro testing, the compositions exhibit high efficacy in treating cutaneous leishmaniasis.